Anti-Mouse Interferon Gamma Antibody (Clone H22) – Purified in vivo GOLD™ Functional Grade

Purified Recombinant Mouse IFN-γ (>98%)

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Anti-Interferon Gamma antibody (IFN-γ) (Clone H22) recognizes an epitope on Mouse IFN-γ. This monoclonal Anti-Interferon Gamma antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Interferon-gamma (IFN-γ) or type II interferon is a dimerized soluble cytokine that is the only member of the type II class of interferons.⁴ It is a cytokine critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control. IFNG is produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the innate immune response, and by CD4 and CD8 cytotoxic T lymphocyte (CTL) effector T cells once antigen-specific immunity develops.⁵ IFN-γ has antiviral, immunoregulatory, and anti-tumour properties.⁶

IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)

1. Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117. PubMed
2. Diamond, MS. et al. (2017) J Virol. 91(22): e01419-17. PubMed
3. Schreiber, RD. et al. (2015) PLoS One.10(5):e0128636. PubMed
4. Goeddel, DV. et al. (1982) Nature 298: 859
5. Wilson, CB. et al. (2007) Adv. Immunol. 96: 41
6. Hume, DA. et al. (2004) J Leukoc Biol. 75: 163
7.) Winkler, E. et al. (2020) Cell 182(4):901-918.e18 Journal Link